Is GGT a better monitoring choice than albumin-to-creatinine ratio on orforglipron?

The case in front of me: GGT · albumin-to-creatinine ratio · orforglipron.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

Is there a defensible reason to prefer one, or is this a coin flip?

The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Headline results, principal programmes

The underlying point is that a sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Keep the full report, not the number. You will need the units and the interval later.

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

edited 3 May 2025 by Dr_Ingrid_Baumgartner — removed a claim I could not source

The short version: a small, well-chosen panel with a baseline beats a large one without.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Research-use compounds are not approved for human use, and no panel makes that safer.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Decide the action for each result before you order the test.